| Methods | D: crossover C: unclear B: double WD: 8/39 J: 1‐2‐1 DU: ‐/3x12w (no washout)/‐ | |
| Participants | N: 39/31 D: 10 migraine with, 21 without aura C: Ad Hoc F: 84% A: 15‐65 years DU: not reported S: neurology outpatient department of a hospital in Denmark | |
| Interventions | P: 120 mg C1: Placebo C2: Tolfenamic acid 300 mg | |
| Outcomes | R: not reported F: 1st period: 6.4 (sd 4.1) vs. 7.6 (6.1) vs. 10.2 (6.8); pooled: 6.6 (sd 4.9) vs. 8.8 (6.9) vs. 6.9 (6.1) AU: trend in favor of tolfenamic acid HI: not reported AEs: 3/31 vs. 3/31 vs. 2/31 Dropouts‐AEs: 2/39 vs. 0/39 vs. 2/39 V: + vs. C1, (‐) vs. C2 | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.